Evidence map›Paper›PMID 41341865›Full record

ReviewInternational journal of nanomedicine2025

Intelligent Nanomedicine Systems Utilizing Diverse Nanoparticles for Osteosarcoma Therapy: A Review.

Jie Cai, Hulin Yang, Zongxian He, Chenghu Wu

Abstract readReview
In one paragraph

Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Green-synthesizedRSC advances · 2026
    Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jie CaiDepartment of Orthopedics, The First People's Hospital of Xiaoshan District, Xiaoshan Affiliated Hospital of Wenzhou Medical University, Hangzhou, 311200, People's Republic of China.
Hulin YangDepartment of Orthopedics, The First People's Hospital of Xiaoshan District, Xiaoshan Affiliated Hospital of Wenzhou Medical University, Hangzhou, 311200, People's Republic of China.
Zongxian HeDepartment of Orthopedics, The First People's Hospital of Xiaoshan District, Xiaoshan Affiliated Hospital of Wenzhou Medical University, Hangzhou, 311200, People's Republic of China.
Chenghu WuDepartment of Biomedical Engineering, Wenzhou Medical University, Wenzhou, 325035, People's Republic of China.ORCID 0000-0003-2143-8581

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteosarcoma and other solid tumor therapies remain urgent clinical challenges. Currently, treatment mainly relies on surgical resection. However, surgery often requires extensive removal of bone and surrounding tissues, which can easily lead to impaired limb function, affect patients' immune and metabolic functions, and increase the risk of recurrence. Smart nanomedicine offers new hope for the treatment of solid tumors. Nanoparticles can enable targeted drug delivery and personalized treatment, reduce damage to normal tissues, and help prevent dysfunction and disability. Postoperative adjuvant nanomedicines can help eliminate residual tumor cells, lower the recurrence rate, control distant metastasis, and improve survival rates. Additionally, nanoparticle-based immunotherapy has shown promising prospects. By integrating artificial intelligence and big data platforms, the development of smart nanomedicine systems can become more efficient, reliable, and tailored to the specific needs of osteosarcoma therapy. However, there are still biosafety, ethical, and regulatory challenges in clinical translation. In the future, it is necessary to further optimize the targeting and biocompatibility of nanocarriers, strengthen research on tumor metabolism, and improve regulatory systems to promote the clinical application and commercial development of multifunctional nanoparticles.

Indexed as

Bone NeoplasmsNanomedicineNanoparticlesOsteosarcomaAnimalsAntineoplastic AgentsArtificial IntelligenceDrug Delivery SystemsHumansImmunotherapyAntineoplastic Agentsartificial intelligencedrug deliveryimmune regulationmetabolic regulationnanomedicinenanoparticles

Identifiers

PMID41341865
PMCPMC12669381

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.